Drug Pricing Throughout the Product Lifecycle: A Work in Progress
- 24 January 2023
- journal article
- editorial
- Published by Elsevier BV in Value in Health
- Vol. 26 (3), 317-319
- https://doi.org/10.1016/j.jval.2023.01.012
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero PriceValue in Health, 2023
- Innovative Public Price Mechanisms for Market Access of Innovative Medicines: A Marriage Between Cost-Effectiveness, Medical Need, and Budget ImpactValue in Health, 2023
- The Influence of US Drug Price Dynamics on Cost-Effectiveness Analyses of BiologicsValue in Health, 2022
- The Value of Medical Innovation Versus Industry RewardsValue in Health, 2022
- Medicare Drug Price Negotiation in the United States: Implications and Unanswered QuestionsValue in Health, 2022
- The Impact on Cost-Effectiveness of Accounting for Generic Drug Pricing: Four Case StudiesValue in Health, 2022
- Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the “Age of Cures” and Their Implications for Dynamic EfficiencyValue in Health, 2022
- Using Multiple Authorized Generics to Maintain High Prices: The Example of EntacaponeValue in Health, 2022
- Comparative Approaches to Drug PricingAnnual Review of Public Health, 2020
- Innovation in the pharmaceutical industry: New estimates of R&D costsJournal of Health Economics, 2016